Our data indicated that before radiotherapy, the low expression level of eotaxin was conducive to the therapeutic response to radiotherapy and the expression of eotaxin was positively correlated with CD68+CD163+M2-like macrophages of NSCLC patients after radiotherapy, suggesting that eotaxin could emerge as a potential marker for the prediction of radiotherapy efficacy and recruitment of CD68+CD163+M2-like macrophages of NSCLC patients in radiotherapy. The gene discussed is CD163; the disease is non-small cell lung carcinoma.